Protease inhibitor-associated hyperglycemia in Mexican patients with HIV infection

Archives of Medical Research

Volumn 31, Issue 1, 2000, Pages 81-84

  Palma Aguirre, Antonio ^a   Halabe Cherem, José ^b   Nellen Hummel, Haiko ^b   Aburto Mejía, Elsa ^b   Ibarra Herrera, Enrique ^b   Ponce Monter, Héctor ^a  

^a U de Invest Medica en Farmacol   (Mexico)

^b HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

HIV infection; Hyperglycemia; Mexican population; Protease inhibitors

Indexed keywords

INDINAVIR; PROTEINASE INHIBITOR; SAQUINAVIR;

ADULT; ARTICLE; DIABETES MELLITUS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MEXICO; PREVALENCE; RISK BENEFIT ANALYSIS;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERGLYCEMIA; MALE; MEXICO;

EID: 0034594453     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0188-4409(99)00069-7     Document Type: Article

References (25)

1. McDonald C.K., Kuritzkes D.R. Human immunodeficiency virus type 1 protease inhibitors. Arch Intern Med. 157:1997;951.
2. Lumpkin MM. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus. FDA Public Health Advisory. June 11, 1997.
3. Dubé M.P., Johnson D.L., Currier J.S., Leedom J.M. Protease inhibitor-associated hyperglycaemia. Lancet. 350:1997;713.
4. Visnegarwala F., Krause K.L., Musher D.M. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med. 127:1997;947.
5. Eastone J.A., Decker C.F. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med. 127:1997;948.
6. Escobedo de la Peña J., Arreola F., Castro-Martínez M.G.et al. Diabetes mellitus en mexico-americanos. Rev Med IMSS (Mex). 34:1996;495.
7. Posadas-Romero C., Yamamoto-Kimura L., Lerman-Garber I.et al. The prevalence of NIDDM and associated coronary risk factors in Mexico City. Diabetes Care. 17:1994;1441.
8. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet. 349:1997;1086.
9. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183.
10. O'Rahilly S., Gray H., Humphreys P.J.et al. Impaired processing of prohormones associated with abnormalities of glucose homeostasis and adrenal function. N Engl J Med. 333:1996;1386.
11. Tezapsidis N., Noctor S., Kannan R., Krieger T.J., Mende-Mueller L., Hook V.Y. Stimulation of "Prohormone Thiol Protease" (PTP) and [Met] encephalin by forskolin. J Biol Chem. 270:1995;1385.
12. Cawley N.X., Pu L.P., Loh Y.P. Immunological identification and localization of yeast aspartic protease 3-like prohormone-processing enzymes in mammalian brain and pituitary. Endocrinology. 137:1996;5135.
13. Noble S., Faulds D. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs. 52:1996;93.
14. Daly A.K., Cholerton S., Gregory W., Idle J.R. Metabolic polymorphisms. Pharmacol Ther. 57:1993;129.
15. Von Moltke L.L., Greenblatt D.J., Schmider J., Harmatz J.S., Shader R.I. Metabolism of drugs by cytochrome P450 3A isoforms. Clin Pharmacokinet. 29(Suppl 1):1995;33.
16. Palma-Aguirre J.A., González-Llaven J., Flores-Murrieta F.J., Castañeda-Hernández G. Bioavailability of oral cyclosporine in healthy Mexican volunteers. evidence for interethnic variability J Clin Pharmacol. 37:1997;630.
17. Castañeda-Hernández G., Hoyo-Vadillo C., Palma-Aguirre J.A., Flores-Murrieta F.J. Pharmacokinetics of oral nifedipine in different populations. J Clin Pharmacol. 33:1993;140.
18. Hoyo-Vadillo C., Castañeda-Hernandez G., Herrera J.E.et al. Pharmacokinetics of nifedipine slow release tablet in Mexican subjects. further evidence for an oxidation polymorphism J Clin Pharmacol. 29:1989;816.
19. Ahsan C.H., Renwick A.G., Macklin B., Challenor V.F., Waller D.G., George F.J. Ethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmacol. 31:1991;399.
20. Ahsan C.H., Renwick A.G., Waller D.G., Challenor V.F., George C.F., Amanullah M. The influence of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther. 54:1993;329.
21. Sowunmi A., Rashid T.J., Akinyinka O.O., Renwick A.G. Ethnic differences in nifedipine kinetics. comparisons between Nigerians, Caucasians and South Asians Br J Clin Pharmacol. 40:1995;489.
22. Rashid T.J., Martin U., Clarke H., Waller D.G., Renwick A.G., George C.F. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol. 40:1995;51.
23. Castañeda-Hernández G., Palma-Aguirre J.A., Montoya-Cabrera M.A., Flores-Murrieta F.J. Interethnic variability in nifedipine disposition. reduced systemic plasma clearance in Mexican subjects Br J Clin Pharmacol. 41:1996;433.
24. Williams P.E.O., Sampson A.P., Green C.P.et al. Disposition and bioavailability of the HIV-proteinase inhibitor, Ro 31-8959, after single doses in healthy volunteers. Br J Clin Pharmacol. Aug;34:1992;155P.
25. Walli R., Demant T. Impaired glucose tolerance and protease inhibitors. Ann Intern Med. 129:1998;837.